Clearances for Rembra CT, Rembra RT, and Areta RT enable high-throughput imaging at scale and elevate precision across the cancer care pathway

Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Rembra platform of scanning systems, including Rembra CT, Rembra RT and Areta RT.

The newly cleared systems are designed to help healthcare providers respond to growing demand for imaging and radiation therapy planning by helping to improve speed, efficiency, and access to high-quality imaging. As imaging volumes and clinical complexity continue to rise, healthcare providers need solutions that can help them work more efficiently while maintaining confidence in clinical decisions.

The Rembra platform of systems also extends the role of CT across both diagnostic radiology and radiation therapy, helping to enable more connected workflows and a coordinated approach to patient care—from rapid assessment in acute settings to precise cancer treatment planning.